Larger bottle sizes of Cystorelin® (gonadorelin) are now available
To provide producers with more flexible administration options, Boehringer Ingelheim has introduced a new 100-mL bottle of Cystorelin® (gonadorelin). This larger packaging allows producers to treat up to 50 cows per bottle, compared to just 15 doses with the 30-mL bottle.
“CYSTORELIN and Synchsure® (cloprostenol sodium) offer dependability and flexibility that can improve overall herd reproductive performance,” said Barbara Petersen, DVM, marketing manager, Boehringer Ingelheim. “We’re excited to provide producers with a larger bottle size of CYSTORELIN, to complement the 100-milliliter SYNCHSURE bottle already offered, for added convenience.”
By using Boehringer Ingelheim’s trusted products, SYNCHSURE and CYSTORELIN, cattle producers can take the guesswork out of their breeding program. When used together, these products provide a shortened time to first service, increased estrus detection efficiency, and improved first-service conception rates.
To learn more about the benefits of incorporating these products into your herd’s reproductive program, visit SyncTheHerd.com. Remember to consult a local veterinarian when developing herd synchronization protocols.
CYSTORELIN IMPORTANT SAFETY INFORMATION: DO NOT USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.
SYNCHSURE IMPORTANT SAFETY INFORMATION: FOR ANIMAL USE ONLY, NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. Women of childbearing age, asthmatics and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. In the early stages, women may be unaware of their pregnancies. SYNCHSURE® (cloprostenol sodium) is readily absorbed through the skin and may cause abortion and/or bronchospasms: Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.
Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
CYSTORELIN® and SYNCHSURE® are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. ©2020 Boehringer Ingelheim Animal Health USA Inc. US-BOV-0037-2020